Trxc Stock Buy Or Sell | Validated | Bundle |

: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook

: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout. trxc stock buy or sell

: KARL STORZ acquired the company primarily for its Senhance Surgical System and the development of the next-generation LUNA™ System , aiming to integrate these into their global endoscopy portfolio. : Leading up to its acquisition, the company

Since the company is now , it is not possible to buy or sell shares on public markets. Since the company is now , it is

: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC)

The ticker is no longer active for trading. TransEnterix, the company originally associated with that symbol, rebranded as Asensus Surgical and changed its ticker to ASXC in March 2021. Subsequently, Asensus Surgical was acquired by KARL STORZ and its stock was officially delisted in August 2024. Stock Status and Delisting

AI responses may include mistakes. For financial advice, consult a professional. Learn more